Drugs / Caduet
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CADUET | — | 2004-01-30 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00332761 | Jun 2006 → Sep 2007 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00081731 Comparator | Apr 2004 → Sep 2013 | atherosclerosis, renal artery obstruction, renovascular hypertension | Baim Institute for Clinical Research | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03504735 Comparator | May 2005 → Jan 2009 | metabolic syndrome X | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Caduet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00081731 ↗ |